The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
C | Cardiovascular system | |
2
|
C09 | Agents acting on the renin-angiotensin system | |
3
|
C09C | Angiotensin II antagonists, plain | |
4
|
C09CA | Angiotensin II antagonists, plain | |
5
|
C09CA07 | Telmisartan |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 40 mg |
| Active Ingredient |
|---|
|
Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist. Telmisartan selectively binds the AT1 receptor. The binding is long-lasting. |
| Document | Type | Information Source | |
|---|---|---|---|
| MICARDIS Tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| MIZART Tablet | MPI, EU: SmPC | Pharmaceutical Benefits Scheme (AU) | |
| TELTARTAN Tablet | MPI, EU: SmPC | Pharmaceutical Benefits Scheme (AU) | |
| TOLURA Tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.